pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$VERAVera Therapeutics, Inc.

$VERA29.79-1.18%
Brisbane, CA, USupdated 9d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1pre_registration: 1
1Phase 21pre_registration
Phase 2
traxivitug
Polyomavirus Infections
pre_registration
atacicept
IgA Nephropathy (Berger's Disease)
Tumor necrosis factor ligand superfamily member 13BTumor necrosis factor ligand superfamily member 13

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Monthly Dosing of Atacicept in IgANactive not recruitingn=90
  • phase2Atacicept in Multiple Glomerular Diseasesrecruitingn=200
  • phase3Atacicept in Subjects With IgA Nephropathyactive not recruitingn=376
  • phase3Atacicept in Subjects With Active Lupus Nephritis (COMPASS)withdrawn
  • phase2A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ataciceptenrolling by invitationn=476
  • phase2A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipientscompletedn=30
🐶 Hiring Signal
No open roles indexed yet — view Vera Therapeutics, Inc. jobs →

News

  • AI chatbots aren’t therapists. But can they finally get men to open up?
    AI chatbots are imperfect therapists. But can they finally get men to talk?
    stat · 8d ago
  • Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
    Also lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.
    biospace · 10d ago
  • Alethio raises $90M to target rare blood cancers
    The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.
    biopharma_dive · 12d ago
  • Merck KGaA makes noise in hematology with $1.1B Silence buy
    Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
    biospace · 28d ago
  • Merck KGaA bets on RNAi with $1.3B Silence buyout
    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
    biopharma_dive · 28d ago
  • Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep
    Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…
    biospace · 29d ago
  • Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
    Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…
    biospace · 29d ago
  • Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
    Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
    fiercebiotech · 29d ago
  • Roche, Ionis RNA drug scores in kidney disease study
    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
    biopharma_dive · 1mo ago
  • Roche kidney drug's Phase 3 win sets up path to accelerated approval
    Roche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phas…
    endpoints · 1mo ago
view all news mentions →
identifiers
ticker
$VERA
SEC CIK
0001831828
country
US
source
sec_tickers
top tags
Infectious Disease1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 41m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?